Gentium S.p.A. Announces Successful Completion Of Defibrotide Phase 1 Study In Japan
11/12/2013 12:55:15 PM
VILLA GUARDIA (COMO), Italy, Nov. 12, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that the medical team from the Phase 1 Trial Unit of the Translational Research Center at the National University Corporation, Hamamatsu University School of Medicine ("HUSM"), Fukushima Medical University ("FMU") has successfully completed the phase 1 clinical study to evaluate the Safety and Pharmacokinetics of Defibrotide (DF) in Healthy Adults.
Help employers find you! Check out all the jobs and post your resume.
comments powered by